share_log

The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer

The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer

美國食品藥品管理局已接受葛蘭素史克的Jemperli（Dostarlimab）與標準護理化療聯合的補充生物製劑許可申請，將治療範圍擴大到所有原發性晚期或複發性子宮內膜癌的成年患者
Benzinga ·  04/24 18:58

The FDA Has Accepted Supplemental Biologics License Application For GSK's Jemperli (Dostarlimab) In Combination With Standard-of-care Chemotherapy To Expand Treatment To All Adult Patients With Primary Advanced Or Recurrent Endometrial Cancer

美國食品藥品管理局已接受葛蘭素史克的Jemperli（Dostarlimab）與標準護理化療聯合的補充生物製劑許可申請，將治療範圍擴大到所有原發性晚期或複發性子宮內膜癌的成年患者

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論